Small cell therapy company Idogen will have to liquidate the company if another solution isn’t found soon, like a reverse merger or the sale of its platform,
as its cash dwindles
.
On Tuesday, Sweden-listed Idogen (STO: $IDOGEN) said it had started conversations around a reverse merger – but there isn’t much time, as a proposal for liquidation will be discussed at its annual general meeting on June 8. Idogen added that unless its technology platform is sold and “yields the desired result,” shareholders can’t count on any financial gain in the case of liquidation.
Unlock this article along with other benefits by subscribing to one of our paid plans.